Mirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) ...

Raymond James Financial Inc. bought a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) during ...

AlphaQuest LLC increased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 969.6% in the 4th quarter ...

Mirum's $400,000-a-year oral drug Livmarli, or maralixibat, was approved in September 2021 to treat Alagille syndrome, a condition that includes persistent itch and a variety of heart and bone issues.

The company’s lead product, Livmarli (maralixibat), has been a key driver ... which is approved for Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC).

Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution ... of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe ...

Mirum has three approved medications: LIVMARLI ® (maralixibat ... the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe ...

LIVMARLI® (maralixibat) oral solution is an orally administered ... It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. three months of age ...

LIVMARLI® (maralixibat) oral solution is an orally ... It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. three months of age and ...